RxDoctor Payments Data

Ronda Evans, APRN

Clinical Nurse Specialist · Little Rock, ARNPI 1447621255

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,173 of the $1,472 with a category attached, or 79.7%. 12 manufacturers reported payments, led by Incyte Corporation at 37.6% of the total. 2025 is the largest year on record at $632, 2.0 times the $309 reported in 2021.

$1,472in general payments, 2019–2025

Across 18 payments — averaging $81.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$553
  • Pharmacyclics LLC, An Abbvie Company$125
  • Geron Corporation$124
  • Genentech, Inc.$103
  • Astellas Pharma US Inc$99
  • Jazz Pharmaceuticals Inc.$96
  • plus $371 from 6 others

What the payments were for

  • Food & beverage$1,17380%
  • Education$29920%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical nurse specialist providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$7,110
Medicare patients
47
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezurockBelumosudil Mesylate42$738,330
PromactaEltrombopag Olamine11$369,482
JakafiRuxolitinib Phosphate22$326,826
TibsovoIvosidenib11$182,412
XareltoRivaroxaban13$7,424
Mycophenolate Mofetil12$4,042
Tacrolimus39$3,551
Voriconazole14$2,341
Sirolimus12$1,058
Acyclovir93$469
Fluconazole15$398
Potassium Chloride20$382
Ondansetron OdtOndansetron11$326
Triamcinolone Acetonide24$291
Famotidine12$241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$553$326,82622 claims
Johnson & JohnsonXarelto$64$7,42413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical nurse specialist providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other clinical nurse specialist in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →